Ajax Health backed Ablacon, Inc. Announces the Formation of Scientific Advisory Board
Ablacon, Inc., an Ajax Health-backed company, announced today the formation of its Scientific Advisory Board (SAB). The SAB will be composed of four internationally recognized thought leaders in the field of electrophysiology to guide Ablacon in its development of Ablamap®, a novel mapping solution to guide treatment of atrial fibrillation (AF).
"We are excited to bring together this distinguished group of experts in electrophysiology at this pivotal time in Ablacon's development," says Duke Rohlen, Ablacon's CEO. "Our team has made enormous progress in product development, scientific validation and clinical demonstration. As we look to the future, we are thrilled to be able to leverage the expertise of this group to bring this innovation to market to enhance patient care in AF."